Johnson & Johnson's TREMFYA (guselkumab) demonstrated significantly higher combined fistula remission rates in adults with perianal fistulizing Crohn's disease at Week 24 compared to placebo in the Phase 3 FUZION study. This marks the first randomized controlled trial in 20 years to show efficacy for this challenging Crohn's disease complication, offering hope for improved management of a debilitating condition. The study's positive results support TREMFYA as a new treatment option, with ongoing research including a head-to-head trial against another IL-23 inhibitor underway.
Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to...
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed...
Johnson & Johnson continues to attract investors with its leaner business model focused on innovative medicine and medical technology after spinning off Kenvue. The company raised its dividend by 3.1%, marking 64 years of consecutive growth, supporte...
With interest rates stabilizing in mid-2026, investors are focusing on Dividend Kings and Aristocrats known for decades of consecutive dividend increases. Johnson & Johnson, Coca-Cola, and McDonald's stand out for their strong Q1 earnings, reasonable...
